ADGI Adagio Therapeutics Inc

Adagio Therapeutics Inc (NASDAQ:ADGI) said it secured manufacturing capacity with third parties to produce its SARS CoV-2 antibody treatment for clinical trials in anticipation of US Food and Drug Administration and other regulations. The Waltham, MA-based clinical-stage biopharmaceutical company focuses on discovering, developing and commercializing antibody-based solutions for infectious diseases with pandemic potential. Adagio has […]
https://www.valuewalk.com/adagio-therapeutics-jumps-629-ranks-to-119th-most-owned-stock-on-the-platform/